Articles
News, editorials, patient stories, and more.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
Blog
What Does a Rheumatologist Actually Do?
What does a rheumatologist actually do? Learn what rheumatologists treat, what happens at your first appointment, what tests they may order,...
Read More — What Does a Rheumatologist Actually Do? »
Blog
“My Labs Are Normal, But I Still Feel Awful”: What to Do Next
Your lab results came back normal, but you still feel awful. What now? Learn what normal test results do and don’t mean, how to document o...
Read More — “My Labs Are Normal, But I Still Feel Awful”: What to Do Next »A New Generation of Targeted Therapies Is Transforming Treatment for Immune Thrombocytopenia
A 2026 systematic review in Frontiers in Pharmacology surveys the rapidly expanding landscape of targeted treatments for ITP, including BTK...
Read More — A New Generation of Targeted Therapies Is Transforming Treatment for Immune Thrombocytopenia »
Blog
What to Bring to Your Endocrinologist Appointment When You Have Type 1 Diabetes
Preparing for an endocrinology appointment with Type 1 diabetes? Learn what to bring, what to track, and which questions to ask so you can m...
Read More — What to Bring to Your Endocrinologist Appointment When You Have Type 1 Diabetes »AbbVie's Rinvoq Wins EU Approval for Alopecia Areata and Vitiligo
The European Commission has approved AbbVie's Rinvoq (upadacitinib) for both severe alopecia areata and non-segmental vitiligo, making it th...
Read More — AbbVie's Rinvoq Wins EU Approval for Alopecia Areata and Vitiligo »Amgen Fights FDA Proposal to Pull ANCA Vasculitis Drug TAVNEOS From the Market
Amgen has submitted new data to the FDA defending TAVNEOS (avacopan), a drug for the rare autoimmune condition ANCA-associated vasculitis, a...
Read More — Amgen Fights FDA Proposal to Pull ANCA Vasculitis Drug TAVNEOS From the Market »Scleroderma Joins Major Cross-Disease Autoimmune Research Initiative
The Foundation for the National Institutes of Health added scleroderma to its AMP AIM research collaboration, backed by more than $9 million...
Read More — Scleroderma Joins Major Cross-Disease Autoimmune Research Initiative »Health Canada Clears New Kidney Drug for IgA Nephropathy
Health Canada approved Novartis's atrasentan (Vanrafia) to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid diseas...
Read More — Health Canada Clears New Kidney Drug for IgA Nephropathy »Teva and Polpharma Ink Global Deal for an Ocrevus Biosimilar in Multiple Sclerosis
Teva and Polpharma Biologics have struck a global licensing deal for a proposed biosimilar version of Ocrevus, the widely used multiple scle...
Read More — Teva and Polpharma Ink Global Deal for an Ocrevus Biosimilar in Multiple Sclerosis »FDA Approves Atacicept for IgA Nephropathy, Adding a Sixth Treatment Option
The FDA granted accelerated approval to atacicept (Trutakna) for IgA nephropathy on July 7, 2026, after the ORIGIN 3 trial showed a 46% redu...
Read More — FDA Approves Atacicept for IgA Nephropathy, Adding a Sixth Treatment Option »FDA Approves Atacicept (Trutakna) for IgA Nephropathy
The FDA has approved atacicept (Trutakna), a new antibody-blocking drug for the autoimmune kidney disease IgA nephropathy, after it reduced...
Read More — FDA Approves Atacicept (Trutakna) for IgA Nephropathy »FDA Clears First BAFF/APRIL Blocker for Kidney Disease Linked to Autoimmunity
The FDA granted accelerated approval to atacicept (Trutakna) for primary IgA nephropathy, the first therapy to block two key immune signalin...
Read More — FDA Clears First BAFF/APRIL Blocker for Kidney Disease Linked to Autoimmunity »